AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
| Revenue (Most Recent Fiscal Year) | $54.32B |
| Net Income (Most Recent Fiscal Year) | $4.86B |
| PE Ratio (Current Year Earnings Estimate) | 14.69 |
| PE Ratio (Trailing 12 Months) | 14.78 |
| PEG Ratio (Long Term Growth Estimate) | 2.11 |
| Price to Sales Ratio (Trailing 12 Months) | 5.35 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 28.44 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 10.39 |
| Pre-Tax Margin (Trailing 12 Months) | 11.51% |
| Net Margin (Trailing 12 Months) | 8.95% |
| Return on Equity (Trailing 12 Months) | 162.28% |
| Return on Assets (Trailing 12 Months) | 14.62% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.87 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.76 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 5.02 |
| Inventory Turnover (Trailing 12 Months) | 5.11 |
| Book Value per Share (Most Recent Fiscal Quarter) | $5.78 |
| Earnings per Share (Most Recent Fiscal Quarter) | $2.79 |
| Earnings per Share (Most Recent Fiscal Year) | $11.11 |
| Diluted Earnings per Share (Trailing 12 Months) | $2.73 |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Common Shares Outstanding | 1.77B |
| Free Float | 1.77B |
| Market Capitalization | $290.83B |
| Average Volume (Last 20 Days) | 5.00M |
| Beta (Past 60 Months) | 0.58 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.25% |
| Percentage Held By Institutions (Latest 13F Reports) | 70.23% |
| Annual Dividend (Based on Last Quarter) | $6.20 |
| Dividend Yield (Based on Last Quarter) | 3.77% |